Ines Moreno-Gonzalez
Overview
Explore the profile of Ines Moreno-Gonzalez including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
52
Citations
1756
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
11.
Moreno-Gonzalez I, Edwards 3rd G, Morales R, Duran-Aniotz C, Escobedo Jr G, Marquez M, et al.
Front Aging Neurosci
. 2022 Feb;
13:815361.
PMID: 35173603
Alzheimer's disease (AD) is one of the leading causes of dementia in late life. Although the cause of AD neurodegenerative changes is not fully understood, extensive evidence suggests that the...
12.
Sanchez-Varo R, Sanchez-Mejias E, Fernandez-Valenzuela J, De Castro V, Mejias-Ortega M, Gomez-Arboledas A, et al.
Front Neurosci
. 2021 Nov;
15:752594.
PMID: 34803589
Alzheimer's disease (AD) is a devastating neurodegenerative disorder characterized by initial memory impairments that progress to dementia. In this sense, synaptic dysfunction and loss have been established as the pathological...
13.
Finger C, Moreno-Gonzalez I, Gutierrez A, Moruno-Manchon J, McCullough L
Mol Psychiatry
. 2021 Oct;
27(2):803-818.
PMID: 34711943
Aging is associated with chronic systemic inflammation, which contributes to the development of many age-related diseases, including vascular disease. The world's population is aging, leading to an increasing prevalence of...
14.
de Oliveira J, Kucharska E, Garcez M, Rodrigues M, Quevedo J, Moreno-Gonzalez I, et al.
Cells
. 2021 Oct;
10(10).
PMID: 34685563
Alzheimer's disease (AD) is the leading cause of dementia worldwide. Most AD patients develop the disease in late life, named late onset AD (LOAD). Currently, the most recognized explanation for...
15.
Moreno-Gonzalez I, Edwards 3rd G, Hasan O, Gamez N, Schulz J, Fernandez-Valenzuela J, et al.
Diagnostics (Basel)
. 2021 Oct;
11(10).
PMID: 34679572
Several common and debilitating neurodegenerative disorders are characterized by the intracellular accumulation of neurofibrillary tangles (NFTs), which are composed of hyperphosphorylated tau protein. In Alzheimer's disease (AD), NFTs are accompanied...
16.
Morales R, Bravo-Alegria J, Moreno-Gonzalez I, Duran-Aniotz C, Gamez N, Edwards Iii G, et al.
Mol Psychiatry
. 2021 May;
26(10):5690-5701.
PMID: 34002023
Previous reports showed that brain Aβ amyloidosis can be induced in animal models by exogenous administration of pre-formed aggregates. To date, only intra-peritoneal and intra-venous administrations are described as effective...
17.
Baglietto-Vargas D, Forner S, Cai L, Martini A, Trujillo-Estrada L, Swarup V, et al.
Nat Commun
. 2021 Apr;
12(1):2421.
PMID: 33893290
The majority of Alzheimer's disease (AD) cases are late-onset and occur sporadically, however most mouse models of the disease harbor pathogenic mutations, rendering them better representations of familial autosomal-dominant forms...
18.
Duran-Aniotz C, Moreno-Gonzalez I, Gamez N, Perez-Urrutia N, Vegas-Gomez L, Soto C, et al.
Acta Neuropathol Commun
. 2021 Mar;
9(1):56.
PMID: 33785065
Amyloid-β (Aβ) misfolding is one of the hallmark pathological features of Alzheimer's disease (AD). AD can manifest with diverse symptomatology including variable rates of cognitive decline, duration of clinical disease,...
19.
Trujillo-Estrada L, Sanchez-Mejias E, Sanchez-Varo R, Garcia-Leon J, Nunez-Diaz C, Davila J, et al.
Neuroscientist
. 2021 Mar;
28(6):572-593.
PMID: 33769131
Alzheimer's disease (AD) is an incurable neurodegenerative disease affecting over 45 million people worldwide. Transgenic mouse models have made remarkable contributions toward clarifying the pathophysiological mechanisms behind the clinical manifestations...
20.
Wu J, Carlock C, Shim J, Moreno-Gonzalez I, Glass 2nd W, Ross A, et al.
Mol Psychiatry
. 2021 Jan;
26(10):5912-5924.
PMID: 33432186
Defective aquaporin4 (AQP4)-mediated glymphatic drainage has been linked to tauopathy and amyloid plaque in Alzheimer's disease. We now show that brain interleukin33 (IL33) is required for regulation of AQP4 expression...